Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

New indication alert: FDA approves AZ’s Lynparza® plus abiraterone for mCRPC

May 31, 2023

The FDA announced that it has approved AstraZeneca’s Lynparza® (olaparib) with abiraterone and prednisone (or prednisolone) for patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an FDA-approved companion diagnostic test.  Following this approval, AstraZeneca announced that it will receive a regulatory milestone payment from MSD, anticipated to be confirmed in Q2 2023 results. 

This news follows the FDA’s Oncologic Drugs Advisory Committee vote to support FDA approval of Lynparza® with abiraterone and prednisone (or prednisolone) for the above indication in April 2023.